Update: Spero Therapeutics Q3 Adj. EPS $(0.16) Beats $(0.47) Estimate
Benzinga Newsdesk 6 days ago
NewsEarningsEarnings Beats
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.47) by 65.96 percent. This is a 23.08 percent decrease over losses of $(0.13) per share
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.47) by 65.96 percent. This is a 23.08 percent decrease over losses of $(0.13) per share from the same period last year.
